A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
NCT02343536
Completed
The goal of the study is to identify a dose and schedule of CC-486 that can be safely administered with R-CHOP. To evaluate the safety and maximum tolerated dose (MTD) or the maximal administered dose (MAD) of CC-486 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with high risk (IPI 2 or more) previously untreated DLBCL or Grade 3B FL. Also, to determine pharmacokinetics (PK) of CC-486 when administered alone and in combination wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2020
Locations: Moffitt Cancer Center, Tampa, Florida +6 locations
Conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Register for Updates
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
NCT00005970
Completed
This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and trastuzumab to see how well they work compared to combination chemotherapy alone in treating women with breast cancer that is human epidermal growth factor receptor 2 (HER2)-positive and has spread to the lymph nodes or high-risk and has not spread to the lymph nodes. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/13/2020
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +156 locations
Conditions: Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Register for Updates
Cardiac Safe Transplants for Systemic Sclerosis
NCT03593902
Terminated
This study is designed to treat systemic sclerosis (scleroderma) patients with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy that is less toxic to your heart.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/10/2020
Locations: Northwestern University, Feinberg School of Medicine, Chicago, Illinois +1 locations
Conditions: Systemic Sclerosis, Scleroderma
Register for Updates
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
NCT00390156
Completed
RATIONALE: Imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2020
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Conditions: Unspecified Adult Solid Tumor
Register for Updates
A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only
NCT00451178
Completed
To compare R-CHOP plus enzastaurin versus R-CHOP for progression-free survival (PFS) time measured in participants with intermediate and/or high risk for diffuse large B-cell lymphoma (DLBCL) receiving first-line treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2020
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Huntsville, Alabama +24 locations
Conditions: Lymphoma
Register for Updates
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
NCT02781467
Terminated
This study will find the highest acceptable treatment dose of cord blood, culture expanded natural killer (NK) cells, a kind of immune cell, in patients with relapsed and/or refractory acute myeloid leukemia. The NK cells will be given with chemotherapy and Recombinant human interleukin 2 (rhIL-2) to help the NK cells expand in the body. The safety of this treatment will be studied and researchers want to learn if NK cells will help in treating the AML.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/20/2020
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +6 locations
Conditions: Leukemia, Myeloid, Acute
Register for Updates
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
NCT00206518
Completed
The purpose of this study is to learn if the biomarker information obtained (learned or received) from the earlier studies can tell us whether or not Taxotere and/or Adriamycin/Cytoxan can cause tumors to become smaller.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/16/2020
Locations: Baylor Breast Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP
NCT00578344
Terminated
Patients are being asked to participate in this study because they have severe sickle cell anemia (SCD) with or without the beta thalassemia trait. Sickle cell anemia is an illness where the red blood cells change shape and can clog up blood vessels. This keeps the body from getting the oxygen it needs. Thalassemia is when the body does not make enough hemoglobin, something that helps the oxygen get to the places it needs to go in the body. The patient may or may not need to get regular blood tr... Read More
Gender:
ALL
Ages:
40 years and below
Trial Updated:
07/16/2020
Locations: Methodist Hospital, Houston, Texas +1 locations
Conditions: Sickle Cell Disease, Hemoglobin SC
Register for Updates
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
NCT00003086
Terminated
RATIONALE: Bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of repeated use of high-dose chemotherapy plus bone marrow transplantation and samarium 153 in treating women who have stage IV breast cancer.
Gender:
FEMALE
Ages:
Between 21 years and 65 years
Trial Updated:
07/10/2020
Locations: Louisiana State University School of Medicine, Shreveport, Louisiana
Conditions: Breast Cancer
Register for Updates
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
NCT00345865
Completed
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, etoposide, and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving colony-stimulating factors, such as G-CSF, helps ste... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
07/10/2020
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota
Conditions: Lymphoma
Register for Updates
Primary Breast Cancer Occurring Concomitant With Pregnancy
NCT00510367
Completed
The goal of this clinical research study is to learn the results of multimodality (chemotherapy, surgery and radiation therapy) treatment of primary breast cancer that occurs at the same time as pregnancy. Researchers want to evaluate the outcome of labor and delivery as well as evaluate the long-term health outcomes of children exposed to chemotherapy while in their mother's womb.
Gender:
FEMALE
Ages:
All
Trial Updated:
07/09/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer, Pregnancy
Register for Updates
Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
NCT01445821
Terminated
ASSIST I was the first randomized trial in patients with scleroderma to not just slow disease progression but rather actually reverse it. It is the first treatment to have ever demonstrated reversal of lung disease in scleroderma with improvement in FVC, total lung capacity (TLC), high-resolution computed tomography (HRCT), and QOL. We now, therefore, purpose to compare the ASSIST I conditioning regimen of cyclophosphamide and rATG to a less intense regimen of rATG/cyclophosphamide/Fludarabine.... Read More
Gender:
ALL
Ages:
Between 17 years and 60 years
Trial Updated:
07/07/2020
Locations: Northwestern University, Chicago, Illinois
Conditions: Scleroderma, Systemic
Register for Updates